Here's a quickie courtesy of Fierce Biotech where they have published 10 promising drugs currently in late stage clinical trials for various cancer indications. All of these have received good press for one site or another and are considered to be among the industry's most promising candidates in the pipeline:
- Carfilzomib - multiple myeloma - Onyx Pharmaceuticals
- Crizotinib (PF-02341066) - lung cancer - Pfizer
- GDC-0449 (vismodegib) - basal cell carcinoma - Roche (Curis)
- OncoVex - advanced melanoma - Amgen (BioVex)
- PLX4032 (RG7204) - melanoma - Plexxikon
- Ponatinib - leukemia - Ariad Pharmaceuticals
- SGN-35 (brentuximab vedotin) - Hodgkin's lymphoma, anaplastic large cell lymphoma - Seattle Genetics
- Tivozanib (AV-951) - advanced renal cell carcinoma - Aveo Pharmaceuticals
- T-DM1 (Trastuzumab-DM1) - breast cancer - Roche (Genentech)
- XL184 (carbozantinib) - prostate cancer - Exelixis
Posted by Bruce Lehr April 4th 2011.
Comments